Literature DB >> 10395867

Comprehensive restriction analysis of the UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child.

L Prix1, K Hamprecht, B Holzhüter, R Handgretinger, T Klingebiel, G Jahn.   

Abstract

Children with innate immunodeficiencies may be at high risk for early development of ganciclovir-resistant human cytomegalovirus (HCMV) infection after bone marrow transplantation (BMT). For early and frequent monitoring of the occurrence of ganciclovir resistance-associated mutations in codons of the UL97 gene, a panel of previously described restriction assays was expanded for use on codons 591, 592, and 603. This technique enabled detection of suddenly emerging ganciclovir-resistant HCMV after BMT in a 7-year-old child with a T cell defect. Resistance emerged among the isolation of a ganciclovir-sensitive HCMV strain 32 days after transplantation, the first detection of genotypical resistance at day 44, and the isolation of resistant HCMV (ID50>12 microM) at day 54. Simple and yet comprehensive methods for therapy surveillance may be important in this patient group, in which the restriction assays proved useful.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395867     DOI: 10.1086/314877

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  High impact of an expanded restriction fragment length polymorphism assay on detection of ganciclovir-resistant UL97 mutants of human cytomegalovirus.

Authors:  Tobias Eckle; Gerhard Jahn; Klaus Hamprecht
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 2.  Human cytomegalovirus intrahost evolution-a new avenue for understanding and controlling herpesvirus infections.

Authors:  Nicholas Renzette; Laura Gibson; Jeffrey D Jensen; Timothy F Kowalik
Journal:  Curr Opin Virol       Date:  2014-08-25       Impact factor: 7.090

3.  Use of time-saving flow cytometry for rapid determination of resistance of human cytomegalovirus to ganciclovir.

Authors:  Gyu-Cheol Lee; Dong-Gun Lee; Su-Mi Choi; Jin-Hong Yoo; Sun-Hee Park; Jung-Hyun Choi; Woo-Sung Min; Ok-Hee Cho; Chan-Hee Lee; Wan-Shik Shin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

4.  Detection of Two Drug-Resistance Mutants of the Cytomegalovirus by High-Resolution Melting Analysis.

Authors:  Xiao-Fan Chen; Tian-Run Li; Hong Yang; Yong Shao; Jie Zhang; Wei Zhang; Bo Yu; Zhun Wei; Bo Wu; Lin Yu
Journal:  J Clin Lab Anal       Date:  2015-05-13       Impact factor: 2.352

5.  Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing.

Authors:  N S Lurain; A Weinberg; C S Crumpacker; S Chou
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 6.  The genetic basis of human cytomegalovirus resistance and current trends in antiviral resistance analysis.

Authors:  S H James; M N Prichard
Journal:  Infect Disord Drug Targets       Date:  2011-10

7.  Pyrosequencing allows the detection of emergent ganciclovir resistance mutations after HCMV infection.

Authors:  Susanne E Kampmann; Birgit Schindele; Luise Apelt; Christoph Bührer; Lars Garten; Katharina Weizsaecker; Detlev H Krüger; Bernhard Ehlers; Jörg Hofmann
Journal:  Med Microbiol Immunol       Date:  2010-12-17       Impact factor: 3.402

Review 8.  Antiviral drug resistance: mechanisms and clinical implications.

Authors:  Lynne Strasfeld; Sunwen Chou
Journal:  Infect Dis Clin North Am       Date:  2010-06       Impact factor: 5.982

Review 9.  Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.

Authors:  Ellen Meijer; Greet J Boland; Leo F Verdonck
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

10.  Dynamics of the emergence of a human cytomegalovirus UL97 mutant strain conferring ganciclovir resistance in a pediatric stem-cell transplant recipient.

Authors:  Katharina Göhring; Tobias Feuchtinger; Elfriede Mikeler; Peter Lang; Gerhard Jahn; Rupert Handgretinger; Klaus Hamprecht
Journal:  J Mol Diagn       Date:  2009-05-28       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.